Keryx Biopharmaceuticals is a commercial stage biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products for patients with renal disease. The Company markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis.

Type
Public
HQ
New York, US
Founded
1998
Size (employees)
193 (est)
Website
keryx.com
Keryx Biopharmaceuticals was founded in 1998 and is headquartered in New York, US
Report incorrect company information

Keryx Biopharmaceuticals Office Locations

Keryx Biopharmaceuticals has offices in Boston and New York
New York, US (HQ)
750 Lexington Ave., 20th Floor
Boston, US
One Marina Park Drive, 12th Floor
Show all (2)
Report incorrect company information

Keryx Biopharmaceuticals Financials and Metrics

Keryx Biopharmaceuticals Financials

Keryx Biopharmaceuticals's revenue was reported to be $60.64 m in FY, 2017
USD

Revenue (FY, 2017)

60.6 m

Gross profit (FY, 2017)

38.7 m

Gross profit margin (FY, 2017), %

63.8%

Net income (FY, 2017)

(163.4 m)

EBIT (FY, 2017)

(101.7 m)

Market capitalization (23-Apr-2018)

517.8 m

Cash (31-Dec-2017)

93.5 m
Keryx Biopharmaceuticals's current market capitalization is $517.8 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

7 m10.8 m13.7 m32 m60.6 m

Revenue growth, %

55%26%134%

Cost of goods sold

37.8 m22 m

Gross profit

(5.8 m)38.7 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

1.2 m2.5 m4.2 m6.8 m9.3 m6.3 m11.8 m15.1 m

Cost of goods sold

76 k304 k3.1 m1.1 m5.1 m18.2 m4.3 m4.4 m

Gross profit

1.1 m2.2 m1.1 m5.8 m4.2 m(11.9 m)7.5 m10.8 m

Gross profit Margin, %

94%88%27%84%45%(187%)64%71%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

55.7 m74.3 m200.3 m111.8 m93.5 m

Accounts Receivable

834 k3.7 m5.2 m8.1 m

Inventories

7.8 m41.9 m12.7 m28.7 m

Current Assets

56.9 m98.6 m249.3 m132.9 m141.6 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

67.7 m105.3 m92 m84.1 m168.8 m131.3 m102.2 m170.5 m155.8 m132.2 m90.9 m140.5 m

Accounts Receivable

156 k195 k136 k151 k1.3 m1.4 m2.6 m4.3 m5.1 m6.2 m8.5 m

Inventories

918 k27.2 m34 m36.7 m42.2 m39.7 m24.3 m12.6 m18.1 m

Current Assets

71.6 m156.4 m138.3 m122 m200.7 m171.4 m147.7 m220.2 m202.7 m160 m119.3 m175.7 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(46.7 m)(111.5 m)(123.1 m)(161.1 m)(163.4 m)

Depreciation and Amortization

54 k306 k596 k1 m937 k

Inventories

(7.8 m)(29.2 m)(2.3 m)(19.5 m)

Accounts Payable

6.8 m10.1 m(9.2 m)88 k24 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(29.1 m)(13.5 m)(35.9 m)(71.2 m)(27.7 m)(54.6 m)(85.4 m)(41 m)(44.7 m)(41.7 m)(23 m)

Depreciation and Amortization

34 k32 k88 k185 k138 k283 k431 k261 k

Inventories

371 k39.7 m24.3 m12.6 m

Accounts Payable

(6.3 m)14.7 m13.1 m21.8 m
USDY, 2017

Revenue/Employee

314.2 k

Financial Leverage

-11.3 x
Show all financial metrics
Report incorrect company information